PROBLEM TO BE SOLVED: To provide a method for therapeutic application of bone-forming cells in the treatment of conditions and bone diseases associated with immunodeficiency or immunosuppression.SOLUTION: According to the present invention, there is provided a therapeutic pharmaceutical composition for treating conditions and bone diseases associated with immunodeficiency or immunosuppression, the composition comprising isolated bone-forming cells exhibiting antigen-presenting cell properties and having expression of HLA-II. Here, the conditions and bone diseases associated with immunodeficiency or immunosuppression include osteoporosis, osteopenia, bone fragility, bone necrosis, bone fracture, microfracture, or osteolysis. In addition, 52.8% to 88.4% of isolated osteogenic cells express HLA-II. The isolated osteogenic cells have expression of alkaline phosphatase (ALP), one or more of type 1 procollagen amino terminal propeptide, osteonectin, bone sialoprotein, etc., and calcify the external environment, as well as express HLA-I.SELECTED DRAWING: None【課題】免疫不全又は免疫抑制と関連する病状及び骨疾患の治療における、骨形成性細胞の治療上の適用方法の提供。【解決手段】抗原提示細胞特性を示し、ＨＬＡ－ＩＩの発現を有する単離骨形成性細胞を含む免疫不全又は免疫抑制と関連する骨の疾患又は病状の治療用医薬組成物であって、ここで、該単離骨形成性細胞は骨芽細胞又は骨細胞であり、該免疫不全又は免疫抑制と関連する骨の疾患又は病状は骨粗鬆症、骨減少症、骨脆弱症、骨の壊死、骨折、微小骨折、又は骨溶解症であり、及び該単離骨形成性細胞の５２．８％～８８．４％がＨＬＡ－ＩＩを発現する、医薬組成物。前記単離骨形成細胞が、アルカリホスファターゼ（ＡＬＰ）の発現を有し、１型プロコラーゲンアミノ末端プロペプチド、オステオネクチン、骨シアロ蛋白質等の１つ以上の発現を有し、外部環境を石灰化し、ＨＬＡ－Ｉを発現する医薬組成物。【選択図】なし
